FDA approves first pre-surgical breast cancer drug Perjeta

FDA approves first pre-surgical breast cancer drug Perjeta

"By making effective therapies available to high-risk patients in the earliest disease setting, we may delay or prevent cancer recurrences," said FDA's Dr. Richard Pazdur, who directs the agency's office of cancer products. Cancer specialists already

3
Like
Save

Comments

Write a comment

*